Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection
Yang, J.; Rao, H.Y.
Zhonghua Gan Zang Bing Za Zhi 26(3): 175-178
2018
ISSN/ISBN: 1007-3418 PMID: 29804389 Accession: 059558534
丙型肝炎是全球范围内导致肝脏疾病的主要原因之一。而慢性丙型肝炎会造成肝纤维化及肝硬化，进而发展至失代偿、肝癌等终末期肝脏疾病。抗病毒治疗能够清除病毒，阻止疾病的进展，从而减少晚期肝病的发生。现旨在讨论抗病毒治疗，包括直接抗病毒药物治疗对慢性丙型肝炎肝纤维化及代偿期和失代偿期肝硬化患者的影响及安全性。.
Full Text Article emailed within 1 workday: $29.90
Related References
Maan, R.; van Tilborg, M.; Deterding, K.; Ramji, A.; van der Meer, A.J.; Wong, F.; Fung, S.; Sherman, M.; Manns, M.P.; Cornberg, M.; Hansen, B.E.; Wedemeyer, H.; Janssen, H.L.A.; de Knegt, R.J.; Feld, J.J. 2016: Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 14(12): 1821-1830.E6Kanda, T.; Nakamoto, S.; Nakamura, M.; Jiang, X.; Miyamura, T.; Wu, S.; Yokosuka, O. 2014: Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection Journal of Clinical and Translational Hepatology 2(1): 1-6
Kang, Y.W.; Baek, Y.H.; Lee, S.W.; Park, S.J.; Yoon, J.S.; Yoon, K.T.; Hong, Y.; Heo, N.Y.; Seo, K.I.; Lee, S.S.; Cho, H.C.; Shin, J.W. 2021: Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study Journal of Korean Medical Science 36(21): E142
Fernández-Yunquera, A.; Rincón, D.; Salcedo, M.; Bañares, R. 2013: Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 26(3): 189-192
Cheng, T.-S.; Liang, P.-C.; Huang, C.-F.; Yeh, M.-L.; Huang, C.-I.; Lin, Z.-Y.; Chen, S.-C.; Huang, J.-F.; Dai, C.-Y.; Hsieh, P.-H.; Chuang, W.-L.; Yu, M.-L. 2021: Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment Kaohsiung Journal of Medical Sciences 37(4): 334-345
Mei, Y.-Y.; Chen, Y.-M.; Wu, Y.-K.; Zhang, X.-H.; Xu, W.-X. 2020: Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection Canadian Journal of Gastroenterology and Hepatology 2020: 8872120
Goel, A.; Bhargava, R.; Rai, P.; Aggarwal, R. 2017: Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 36(3): 227-234
Parkash, A.; Merchant, A.A.; Ahmed, S.H.; Hussain, W.; Hayat, M.; Memon, N.A. 2022: Effectiveness and Safety of Direct Acting Antiviral Agents in Thalassaemic Patients with Chronic Hepatitis C Journal of Ayub Medical College Abbottabad: Jamc 34(3): 447-451
Francis, A.K.; Beaudoin, F.L.; Naidjate, S.S.; Berard-Collins, C.; Zullo, A.R. 2020: Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents Rhode Island Medical Journal 103(5): 35-40
Liu, C.-H.; Liu, C.-J.; Su, T.-H.; Fang, Y.-J.; Yang, H.-C.; Chen, P.-J.; Chen, D.-S.; Kao, J.-H. 2017: Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection Open Forum Infectious Diseases 4(1): Ofx028
Hunyady, B.él.; Kovács, B.áz.; Battyáni, Z. 2011: Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection Orvosi Hetilap 152(50): 1997-2009
Karimi-Sari, H.; Rezaee-Zavareh, M.S. 2020: Non-atherosclerotic cardiac manifestations of chronic hepatitis C virus infection in the era of direct-acting antiviral agents Atherosclerosis 298: 70
Conteduca, V.; Sansonno, D.; Russi, S.; Pavone, F.; Dammacco, F. 2014: Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents Journal of Infection 68(1): 1-20
Gupta, N.; Manirambona, L.; Shumbusho, F.; Kabihizi, J.; Murangwa, A.; Serumondo, J.; Makuza, J.D.; Nsanzimana, S.; Muvunyi, C.M.; Mukabatsinda, C.; Musabeyezu, E.; Camus, G.; Grant, P.M.; Kateera, F. 2022: Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial LANCET. Gastroenterology and Hepatology 7(6): 542-551
Welsch, C.; Jesudian, A.; Zeuzem, S.; Jacobson, I. 2012: New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives Gut 61(Suppl 1): I36-I46
Asselah, T; Marcellin, P; Schinazi, R F. 2018: Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International 38: 7-13
Zanaga, L.P.; Miotto, N.; Mendes, L.C.; Stucchi, R.S.B.; Vigani, A.G. 2016: Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents Brazilian Journal of Medical and Biological Research 49(11): E5504
Asselah, T.; Marcellin, P.; Schinazi, R.F. 2018: Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International: Official Journal of the International Association for the Study of the Liver 38(Suppl 1): 7-13
Enomoto, M.; Tamori, A.; Murakami, Y.; Kawada, N. 2014: Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents Hepatology Research: the Official Journal of the Japan Society of Hepatology 44(4): 371-376
Dultz, G.; Müller, T.; Petersen, J.ör.; Mauss, S.; Zimmermann, T.; Muche, M.; Simon, K.-G.; Berg, T.; Zeuzem, S.; Hüppe, D.; Böker, K.; Wedemeyer, H.; Welzel, T.M.; Günther, R.; Hinrichsen, H.; Heyne, R.; Roth, J.; Goeser, T.; Ullrich, R.; John, C.; Hofmann, W.P.; Teuber, G.; Möller, H.ör.; Baumgarten, A.; Schwenzer, J.; Pathil, A.; Kraus, M.R.; Weber, A.; Jung, M.-C.; Gerken, G.; Antoni, C.; Doss, M.F.; Schober, A.; Hoffstadt, M.; Lucadou, A.V.; Steffens, H.; Klinker, H.; Geier, A.; Klausen, G.; Buggisch, P.; Cornberg, M.; Sarrazin, C.; Manns, M.P.; Niederau, C.; Protzer, U.; Schirmacher, P. 2018: Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry Drugs and Aging 35(9): 843-857